Tempus|HRD does not require any additional tissue from the patient and features unique positivity thresholds for Ovarian Cancer, Breast Cancer, and Pancreatic Cancer, along with a general threshold for all other solid tumors. A patient's HRD status has been shown to identify whether or not they are a good candidate for PARP inhibitors and platinum-based chemotherapy. It analyzes 18 of the commonly mutated genes in the HR pathway and calculates a genome-wide loss-of-heterozygosity (LOH) score to give clinicians a comprehensive view into a patient's ability to repair cellular damage.
Tempus hrd full#
Tempus|HRD is a DNA-based test, available as a supplementary option to xT, the company's signature broad-panel genomic sequencing test that measures 648 genes, along with the full transcriptome. "With our additional HRD and capabilities, we are able to further expand the data we can provide oncologists at the point of care, advancing our collective ability to be more precise for the benefit of patients." "Our existing suite of genomic sequencing tests provide physicians with critical data that informs patient care across solid tumor and liquid biopsy profiling," said Eric Lefkofsky, Founder and CEO. Tempus|HRD, a test that identifies a patient's homologous recombination deficiency (HRD) status, and Tempus|, a test which predicts the tissue of origin () for tumors, will both launch this summer in the U.S. In the case of DPYD, the test helps physicians to better identify patients at potential risk for toxicity to 5-FU/Capecitabine chemotherapy.CHICAGO, (GLOBE NEWSWIRE) - Tempus, a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare, announced the launch of two new oncology tests designed to equip physicians with even more precise genomic data in an effort to improve therapeutic outcomes. Each of these tests is designed to predict specific biological signals or clinical endpoints, ultimately supporting physicians in their decision-making as they seek to make more informed decisions for their patients. Tempus’ platform generates the type of rich sequencing data required to develop a novel class of predictive algorithms that can be introduced in the clinic to support personalized patient treatment. Like other algorithmic tests offered by Tempus, such as our Homologous Recombination Deficiency (HRD) and Tumor Origin (TO) test, DPYD is available as an add-on option for physicians ordering Tempus’ xT solid tumor broad-panel assay, streamlining the ordering process and providing a comprehensive patient profile in the report. The test assesses for relevant mutations in the DPYD (dihydropyrimidine dehydrogenase) gene and helps physicians better identify patients at potential risk for toxicity to certain chemotherapy, aiming to avoid adverse effects. Tempus’ platform brings research to life with predictive algorithms that screen cancer patients for mutations in the DPYD geneĬHICAGO, October 26, 2021-( BUSINESS WIRE)-Tempus, a leader in artificial intelligence and precision medicine, today announced its new DPYD algorithm as its most recent addition to its growing collection of predictive algorithm laboratory-developed tests.
0 kommentar(er)
